Patents on brain permeable nanoparticles

Recent Patents on CNS Drug Discovery

Volumn 8, Issue 3, 2013, Pages 220-234

  Gulati, Monica ^a   Chopra, Dimple S ^b   Singh, Sachin K ^a   Saluja, Vikrant ^c   Pathak, Purnima ^d   Bansal, Parikshit ^e  

^a LOVELY PROFESSIONAL UNIVERSITY   (India)

^b PUNJABI UNIVERSITY   (India)

^c PCTE Institute of Pharmacy   (India)

^d Heron India ^*  (India)

^e Excellion Innovations and Inventions Pvt Limited   (India)

Author keywords

Blood brain barrier; Nanoparticles; Neurotherapeutics; Neurotoxicity; Patents; Polymeric nanoparticles

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; CYANOACRYLATE DERIVATIVE; NANOPARTICLE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; PRODRUG; SOLVENT;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; COACERVATION; DIFFUSION; DISPERSION; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; EMULSION; EVAPORATION; GELATION; HUMAN; INTRACEREBRAL DRUG ADMINISTRATION; LIPOSOMAL DELIVERY; NEUROLOGIC DISEASE; NEUROMODULATION; NONHUMAN; OLFACTORY SYSTEM; PARTICLE SIZE; PATENT; POLYMERIZATION; PRIORITY JOURNAL; SUPERCRITICAL FLUID;

BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; PATENTS AS TOPIC;

EID: 84892545161     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574889808666131128105141     Document Type: Article

References (203)

1. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: A way to deliver drugs to the brain. Int J Pharm 2005; 298: 274-92.
2. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Carlo, R. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 2007; 59: 454-77
3. Moos T, Morgan EH. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat. J Neurochem 2001; 79: 119-29.
4. Lo EH, Singhal AB, Torchilin VP, Abbott NJ. Drug delivery to damaged brain. Brain Res Rev 2001; 38: 140-8.
5. Bodor N, Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev 1999; 36: 229-54.
6. Terasaki T, Hosoya K. The blood-brain barrier efflux transporters as a detoxifying system for the brain. Adv Drug Deliv Rev 1999; 36: 195-209.
7. Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005; 108: 193-214.
8. Chivukula V, Chhabria MT. Blood Brain Barriers: Smuggling Past the Barricades. Ind J Pharm Sci 2004; 66: 259-64.
9. Kornblith PL, Walker M. Chemotherapy for malignant gliomas. J Neurosurg 1988; 68: 1-17.
10. Chen Y, Dalwadi G, Benson HAE. Drug delivery across the bloodbrain barrier. Curr Drug Deliv 2004; 1: 361-76.
11. De Boer AG, Gaillard PJ. Strategies to improve drug delivery across the blood-brain barrier. Clin Pharmacokinet 2007; 46: 553-76.
12. Neuwelt EA, Rapoport SI. Modification of the blood-brain-barrier and the chemotherapy of malignant brain tumors. Fed Proc 1984; 43: 214-19.
13. Emerich DF, Snodgrass P, Pink M, Bloom F, Bartus RT. Central analgesic actions of loperamide following transient permeation of the blood-brain barrier with Cereport (RMP-7). Brain Res 1998; 801: 259-66.
14. Siegal T. In: Kobiler D, Lustig S, Shapira S, Eds. Blood Brain barrier: Drug Delivery and brain pathology, Springer. 2002; 251-72.
15. Naito, A.T. Method of opening the blood brain barrier. WO020023848 (2002).
16. Saija A, Princi P, De Pasquale A, Costa G. Arecoline, but not haloperidol, induces changes in the permeability of the blood-brain barrier in the rat. J Pharm Pharmacol 1990; 42: 135-8.
17. Neuwelt, E.A. Method for diagnostically imaging lesions in the brain inside a blood-brain barrier. US5059415A (1991).
18. Neuwelt, E.A. Differential delivery of therapeutic agents across the blood brain barrier. US5124146A (1992).
19. Neuwelt, E.A. Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates. WO8911299 A1 (1989).
20. Malfroy-Camine, B. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability. US5112596A (1992).
21. Emerich DF, Dean RL, Osborn C, Bartus RT. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: From concept to clinical evaluation. Clin Pharmacokinet 2001; 40: 105-23.
22. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cellular Mol Neurobiol 2000; 20:131-47.
23. Kozarich, J.W. Increasing blood-brain barrier permeability with permeabilizer peptides. WO9218529A1 (1992).
24. Tomasz, A., Tuomanen, E. Methods and compositions for reversibly permealizing the blood brain barrier. WO919116064 (1991).
25. Rubin, L., Seth, P., Heidi, H., Theodore, A.Y. Blood-brain barrier model. US5260210A (1993).
26. Banks, W.A., Kumar, V.B., Darling, T., Clayton, R. Modulation of blood brain barrier protein expression. US 0196393A1 (2010).
27. Bynoe, M.S. Modulation of blood brain barrier permeability. WO2009114533A3 (2009).
28. O'Reilly, M.A., Hynynen, K.H. System and method for controlling focused ultrasound treatment. US0006106A1 (2013).
29. Johansson BB, Nordborg C, Westergren I. In: Johansson BB, Owman C, Widner H, Eds. Pathophysiology of the blood brain barrier. Amsterdam: Fenstrom Foundation Series 1990:145-57.
30. Begley D, Brightman MW. In: Prokai, L, Prokai-Tatrai K, Eds. Peptide transport and delivery into the central nervous system. Progress in drug research. Birkhauser Verlag 2003: 39-78.
31. Bodor N, Buchwald P. Brain-targeted drug delivery: Experiences to date. Am J Drug Targ 2003; 1:13-26.
32. Begley D. ABC transporters and the blood-brain barrier. Curr Pharm Design 2004; 10:1295-312.
33. Neuwelt EA, Rapoport SI. Modification of the blood-brain-barrier and the chemotherapy of malignant brain tumors. Fed Proc 1984; 43: 214-19.
34. Anderson BD. Prodrugs for improved CNS delivery. Adv Drug Deliv Rev 1996; 19: 171-202.
35. Haradahira T, Zhang MR, Maeda J, Okauchi T, Kida T, Kawabe K et al. A prodrug of NMDA/glycine site antagonist, L-703,717 with improved BBB permeability: 4-Acetoxy derivative and its positronemitter labeled analog. Chem Pharm Bull 2001; 49:147-50.
36. Batrakova EV, Kabanov AV. In: Touitou E, Barry BW, Eds. Enhancement in drug delivery. CRC Press 2006: 593-614.
37. Bodor N, Brewster ME. In: Juliano RL. Ed, Targeted drug delivery. Springer. 1991: 231-84.
38. Shashoua, V.E. Fatty acid-neuroactive drug conjugate as a prodrug. US4933324A (1989).
39. Shashoua, V.E. Fatty acid drug conjugate for delivery of the drug across the blood brain barrier. WO89007938 (1989).
40. Chung, C.K., Du, J., Kotra, L., Manouilov, K.K., Schinazi, R. Prodrug azide compositions and compounds. US6271212B1 (2001).
41. Ekwuribe, N.N., Rhadakrishnan, B., Price, C.H., Anderson, W., Ansari, A.M. Methods for delivery therapeutic compounds across the blood-brain barrier. US20046703381 (2004).
42. Ternansky, R. Novel drugs for Dementia. WO07038772 (2007).
43. Bodor, N.S. Redox systems for brain-targeted drug delivery. US5017566 A (1991).
44. Bodor, N.S. Brain-specific drug delivery. US5187158 (1993).
45. Bodor, S.N. Brain-enhanced delivery of neuroactive peptides by sequential metabolism. WO1994006450A1 (1994).
46. Schlesinger, D. Lipophilic peptide-based carriers for targeted drug delivery using rational drug-binding design. EP0670728A1 (1995).
47. Menon, D.K., Murphy, M.P., Aigbirhio, F.I., Smith, R.A. Lipophilic cationic probe for PET-imaging. US20130064768A1 (2013).
48. Kroll RA, Pagel MA, Muldoon LL, Roman GS, Neuwelt EA. Increasing volume of distribution to the brain with interstitial infusion: Dose, rather than convection, might be the most important factor. Neurosurg 1996; 38: 752-4.
49. Chauhan NB. Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain. Nucl Acid Drug Dev 2002; 12: 353-7.
50. Sabel, B.A., Frrese, A., Saltzman, W.M. Controlled drug delivery system for treatment of neural disorders. US4883666 (1989).
51. Grossman, S.A., Leong, K.W., Lesser, G., Lo, H. Subcutaneous implant. WO96000047 (1996).
52. Weber EL, Goebel EA. Cerebral edema associated with Gliadel wafers: Two case studies. Neuro-oncol 2005; 7: 84-9.
53. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J Pharm 2001; 218: 75-80.
54. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003; 87: 187-98.
55. Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: Fact or fiction? J Drug Target 1998; 5: 415-41.
56. Bradbury MW, Cserr HF, Westrop RJ. Drainage of cerebral interstitial fluid into deep cervical lymph of the rabbit. Am J Physiol 1981; 240: F329-36.
57. Sakane T, Akizuki M, Yamashita S, Nadai T, Hashida M, Sezaki H. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: The relation to the lipophilicity of the drug. Chem Pharm Bull 1991; 39: 2456-8.
58. Temsamani J, Rousselle C, Rees AR, Scherrmann, JM. Vector mediated drug delivery to the brain. Expert Opin Biol Ther 2001; 1: 773-82.
59. Hussain, A., Dittert, L.W., Traboulsi, A. Brain delivery of folic acid for the prevention of alzheimer's disease and stroke. US2006369058 (2002).
60. Talegaonkar S, Mishra PR. Intranasal delivery: An approach to bypass the blood brain barrier. Ind J Pharmacol 2004; 36: 140-7.
61. Langer R. Biomaterials in drug delivery and tissue engineering: One laboratory's experience. Acc Chem Res 2000; 33: 94-101.
62. Friden, P.M. Transferrin receptor specific antibodyneuropharmaceutical or diagnostic agent conjugates. US5182107A (1993).
63. Friden, P.M. Transferrin receptor specific antibodyneuropharmaceutical agent conjugates. US5154924 (1992).
64. Pardridge, W.M. Cationized antibodies for delivery through the blood-brain barrier. US5004697A (1991).
65. Pardridge, W.M. Chimeric peptides for neuropeptide delivery through the blood-brain barrier. US4801575 A (1989).
66. Pardridge, W.M., Schimmel, P.R. Chimeric peptides for neuropeptide delivery through the blood-brain barrier. US4902505 A (1990).
67. Poduslo, J.F., Curran, G.L. Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents. US5670477 A (1997).
68. Schynder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2005; 2: 99-107.
69. Micklus, M.J. Targeting of liposomes to the blood-brain barrier. EP0652775B1 (2000).
70. Huwyler, J., Pardridge, W.M. Transport of liposomes across the blood brain barrier. WO1998022092 (1998).
71. Pardridge, W.M. Non-invasive gene targeting to the brain. US6372250B1 (2002).
72. Greig, J.N., Micklus, M.J., Rapoport, S.I. Targeting of liposomes to the blood brain barrier. WO94002178 (1994).
73. Pardridge WM. Lipid mediated transport and carrier mediated transport of small molecules. In: Drug targeting: The future of brain drug. Cambridge University Press. 2001; 36-81.
74. Redelmeier, T., Luz, M. Liposomal composition for convectionenhanced delivery to the central nervous centre. WO2010057317 (2010).
75. Langer R. Biomaterials in drug delivery and tissue engineering: One laboratory's experience. Acc Chem Res 2000; 33: 94-101.
76. Bhadra D, Bhadra S, Jain P, Jain NK. Pegnology: A review of PEGylated systems. Pharmazie 2002; 57: 5-29.
77. Kommareddy S, Tiwari SB, Amiji MM. Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technol Cancer Res Treat 2005; 4: 615-25.
78. Lee M, Kim SW. Polyethylene glycol-conjugated copolymers for plasmid DNA delivery. Pharm Res 2005; 22: 1-10.
79. Kreuter J. Nanoparticles. In Kreuter J, Ed. Colloidal drug delivery systems, Marcel Dekker 1994: 219-342.
80. Reverchon E, Adami R. Nanomaterials and supercritical fluids. J Supercrit Fluids 2006; 37: 1-22.
81. Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, DeSimone JM. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J Am Chem Soc 2005; 127: 10096-100.
82. Kompella UB, Bandi N, Ayalasomayajula SP. Poly (lactic acid) nanoparticles for sustained release of budesonide. Drug Deliv Technol 2001; 1: 1-7.
83. Ravi MN, Bakowsky U, Lehr CM. Preparation an characterization of cationic PLGA nanospheres as DNA carriers. Biomat 2004; 25: 1771-7.
84. Li YP, Pei YY, Zhou ZH, Zhang XY, Gu ZH, Ding J, et al. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-[alpha] carriers. J Control Release 2001; 71: 287-96.
85. Kwon, HY, Lee JY, Choi SW, Jang Y, Kim JH. Preparation of PLGA nanoparticles containing estrogen by emulsificationdiffusion method. Colloids Surf A: Physicochem Eng. Aspects 2001; 182: 123-30.
86. Zambaux MF, Bonneaux F, Gref R, Maincent P, Dellacherie E, Alonso MJ, et al. Influence of experimental parameters on the characteristics of poly (lactic acid) nanoparticles prepared by double emulsion method. J Control Release 1998; 50: 31-40.
87. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparation of biodegradable nanoparticles of water-soluble and insoluble drugs with D, Llactide/ glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Control Release 1993; 25: 89-98.
88. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J Pharm 2001; 218: 75-80.
89. Boudad H, Legrand P, Lebas G, Cheron M, Duchene D, Ponchel G. Combined hydroxypropyl-[beta]-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm 2001; 218: 113-24.
90. Puglisi G, Fresta M, Giammona G, Ventura CA. Influence of the preparation conditions on poly(ethylcyanoacrylate) nanocapsule formation. Int J Pharm 1995; 125: 283-87.
91. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoprticles as protein carriers. J Appl Polymer Sci 1997; 63: 125-32.
92. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 1997; 14: 1431-6.
93. Jung J, Perrut M. Particle design using supercritical fluids: Literature and patent survey. J Supercritic Fluids 2001; 20: 179-219.
94. Thote AJ, Gupta RB. Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release. Nanomedicine: Nanotech Biol Med 2005; 1: 85-90.
95. Grislain L, Couvrer P, Lenaerts V. Pharmacokinetics and distribution of a biodegradable drug carrier. Int J Pharm 1983; 15: 333-45.
96. Kreuter J. Nanoparticles and micro particles for drug and vaccine delivery. J Anat 1996; 189: 503-5.
97. Troster SD, Muller U, Kreuter J. Modification of the body distribution of poly (methyl methyl methylacrylate) nanoparticles by coating with surfactants. Int J Pharm 1990; 61: 85-100.
98. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate-80 coated nanoparticles. Pharm Res 1999; 16: 1564-9.
99. Couvreur P, Tulkens P, Roland M, Trouet A, Speiser P. Nanocapsules: A new type of lysosomotropic carrier. FEBS Lett 1977; 84: 323-6.
100. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. Poly (alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 2003; 55: 519-48.
101. Guise V, Drouin JY, Benoit J, Mahuteau J, Dumont P, Couvreur P. Vidarabine-loaded nanoparticles: A physicochemical study. Pharm Res 1990; 7: 736-41.
102. Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 1999; 16: 1836-42.
103. Olivier JC, Vauthier C, Taverna M, Puisieux F, Ferrier D, Couvreur P. Stability of orosomucoid-coated polyisobutylcyanoacrylate nanoparticles in the presence of serum. J Control Release 1996; 40: 157-68.
104. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez-Decampeneere D, Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int J Pharm 1983; 15: 335-45.
105. Douglas SJ, Davis SS, Illum L. Biodistribution of poly (butyl 2-cyanoacrylate) nanoparticles in rabbits. Int J Pharm 1986; 34: 145-52.
106. Waser PG, Muller U, Kreuter S, Munz K, Kaiser E, Pfluger B. Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradiography in mice. Int J Pharm 1987; 39: 213-27.
107. Simeonova M, Ivanova T, Raikova E, Georgieva M, Raikov Z. Tissue distribution of polybutylcyanoacrylate nanoparticles carrying spin-labelled nitrosourea. Int J Pharm 1988; 43: 267-71.
108. Verdun C, Brasseur F, Vranckx H, Couvreur P, Roland M. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother Pharmacol 1990; 26: 13-8.
109. Lobenberg R, Araujo L, von Briesen H, Rodgers E, Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J Control Release 1998; 50: 21-30.
110. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999; 16: 1564-9.
111. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004; 109: 759-67.
112. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1997; 14: 325-8.
113. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate study. J Microencapsul 1998; 15: 67-74.
114. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65-81.
115. Allemann E, Gravel P, Leroux JC, Balant L, Gurny R. Kinetics of blood component adsorption on poly(D, L-lactic acid) nanoparticles: Evidence of complement C3 component involvement. J Biomed Mater Res 1997; 37: 229-34.
116. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic up take and plasma protein adsorption. Colloids Surfaces: Biointerfaces B 2000; 18: 301-13.
117. Lode J, Fichtner I, Kreuter J, Berndt A, Diederichs JE, Reszka R. Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly(methylmethacrylate) nanoparticles in experimental tumor models. Pharm Res 2001; 18: 1613-19.
118. Darius J, Meyer FP, Sabel BA, Schroeder U. Influence of nanoparticles on the brain-to-serum distribution and the metabolism of valproic acid in mice. J Pharm Pharmacol 2000; 52: 1043-7.
119. Schroeder U, Schroeder H, Sabel BA. Body distribution of 3Hlabelled dalargin bound to poly (butyl cyanoacrylate) nanoparticles after i.v. injections to mice. Life Sci 2000; 66: 495-502.
120. Calvo PP, Gouritin B, Chacun H, Desmaële D, D'Angelo J, Noel JP et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001; 18: 1157-66.
121. Azmin MN, Stuart JF, Florence AT. The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother Pharmacol 1985; 14: 238-42.
122. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly (butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 2000; 49: 103-09.
123. Vert M, Schwach G, Engel R, Coudane J. Something new in the field of PLA/GA bioresorbable polymers. J Control Release 1998; 53: 85-92.
124. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28: 5-24.
125. Li S. Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. J Biomed Mater Res 1999; 48: 342-53.
126. Von Burkersroda F, Gref R, Gopferich A. Erosion of biodegradable block copolymers made of poly(D, L-lactic acid) and poly-(ethylene glycol). Biomat 1997; 18: 1599-607.
127. Quellec P, Gref R, Perrin L, Dellacherie E, Sommer F, Verbavatz JM, et al. Protein encapsulation within polyethylene glycol-coated nanospheres. I. Physicochemical characterization. J Biomed Mater Res 1998; 42: 45-54.
128. Vittaz M, Bazile D, Spenlehauer G, Verrecchia T, Veillard M, Puisieux F, et al. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials 1996; 17: 1575-81.
129. Quellec P, Gref R, Dellacherie E, Sommer F, Tran MD, Alonso MJ. Protein encapsulation within polyethylene glycol-coated nanospheres. II. Controlled release properties. J Biomed Mater Res 1999; 47: 388-95.
130. Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. Protein C-loaded monomethoxypoly (ethylene oxide)-poly(lactic acid) nanoparticles. Int J Pharm 2001; 212: 1-9.
131. Working PK, Newman MS, Johnson J, Cornacoff JB. Safety of poly (ethylene glycol) and poly (ethylene glycol) derivatives. In: Poly (ethylene glycol): chemistry and biological applications ACS Symposium Series. American Chemical Society 1997; 680: 45-57.
132. Lemoine D, Francois C, Kedzierewicz F, Preat V, Hoffman M, Maincent P. Stability study of nanoparticles of poly(epsiloncaprolactone), poly(D, L-lactide) and poly (D, L-lactide-coglycolide). Biomat 1996; 17: 2191-7.
133. Plard JP, Didier B. Comparison of the safety profiles of PLA50 and Me. PEG-PLA50 nanoparticles after single dose intravenous administration to rat. Colloids Surfaces B: Biointerfaces 1999; 16: 173-83.
134. Stolnik S, Dunn SE, Garnett MC, Davies MC, Coombes AG, Taylor DC, et al. Surface modification of poly (lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm Res 1994; 11: 1800-8.
135. Verrecchia T, Spenlehauer G, Bazile DV, Murry-Brelier A, Archimbaud Y, Veillard M. Non-stealth (poly(lactic acid/albumin) and stealth (poly(lactic acid-polyethylene glycol) nanoparticles as injectable drug carriers. J Control Release 1995; 36: 49-61.
136. Le Ray AM, Vert M, Gautier JC, Benoi{dotless}̂t JP. Fate of [14C] poly (-lactide-co-glycolide) nanoparticles after intravenous and oral administration to mice. Int J Pharm 1994; 106: 201-11.
137. Li Y, Pei Y, Zhang X, Gu Z, Zhou Z, Yuan W, et al. PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats. J Control Release 2001; 71: 203-11.
138. Moghimi SM, Hunter AC, Murray JC. Long-circulating and targetspecific nanoparticles: Theory to practice. Pharmacol Rev 2001; 53: 283-318.
139. Sahli H, Tapon-Bretaudière J, Fischer AM, Sternberg C, Spenlehauer G, Verrecchia T, et al. Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of the coagulation system. Biomat 1997; 18: 281-88.
140. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S. 'Stealth' corona-core hagocytes system. J Pharm Sci 1995; 84: 493-8.
141. Zambaux MF, Faivre-Fiorina B, Bonneau F, Marchal S, Merlin JL, Dellacherie E, et al. Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig. Biomat 2000; 21: 975-80.
142. Kreuter, J., Karkevich, D.A., Sable, B.A., Alayutdin, R.N. WO95022963 (1995).
143. Ding H, Wu F, Nair MP. Image guided drug delivery to the brain using nanotechnology. Drug Discov Today 2013; doi: 10.1016/j.drudis.2013.06.010. [Epub ahead of print].
144. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-b production in vivo. Sci Transl Med 2011; 3(84): 84ra43.
145. Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res 2010; 27: 1759-71.
146. Masserini M. Nanoparticles for Brain Drug Delivery. ISRN Biochemistry 2013; 2013: Article ID 238428, 18.
147. Wu J, Wang C, Sun J, Xue Y. Neurotoxicity of silica nanoparticles: Brain localization and dopaminergic neurons damage pathways. ACS Nano 2011; 5: 4476-89.
148. Ze Y, Zheng L, Zhao X, Gui S, Sang X, Su J, et al. Molecular mechanism of titanium dioxide nanoparticles-induced oxidative injury in the brain of mice. Chemosphere 2013; 92:1183-9.
149. Dakwar GR, Abu Hammad I, Popov M, Linder C, Grinberg S, Heldman E, et al. Delivery of proteins to the brain by bolaamphiphilic nano-sized vesicles, J Control Release 2012; 160: 315-21.
150. Jin J, Bae KH, Yang H, Lee SJ, Kim H, Kim Y, et al. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjugate Chemistry 2011; 22: 2568-72.
151. Chuang VTG, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002; 19: 569-77.
152. Parikh T, Bommana MM, Squillante E. Efficacy of surface charge in targeting pegylated nanoparticles of sulpiride to the brain. Eur J Pharm Biopharm 2010; 74: 442-50.
153. Liu X, An C, Jin P, Liu X, Wang L. Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia. Biomat 2013; 34: 817-30.
154. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti HIV drugs. Biomat 2008; 29: 4429-38.
155. Rao KS, Labhasetwar V. Trans-activating transcriptional activator (TAT) peptide-mediated brain drug delivery. J Biomed Nanotech 2006; 2: 173-85.
156. Liu L, Venkatraman SS, Yang YY, Guo K, Lu J, He B, et al. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood brain barrier. Biopolym 2008; 90: 617-23.
157. Xu K, Wang H, Liu L, Xu W, Sheng J, Fan W, et al. Efficacy of CG (3) R (6) TAT nanoparticles self-assembled from a novel antimicrobial peptide for the treatment of Candida albicans meningitis in rabbits. Chemoth 2011; 57: 417-25.
158. Xia H, Gao X, Gu G, Liu Z, Hu Q, Tu Y, et al. Penetratinfunctionalized PEGPLA nanoparticles for brain drug delivery. Int J Pharmacol 2012; 436: 840-50.
159. Xu Q, Wang CH, Pack DW. Polymeric carriers for gene delivery: Chitosan and poly (amidoamine) dendrimers. Curr Pharm Design 2010; 16: 2350-68.
160. Bao H, Jin X, Li L, Lv F, Liu T. OX26 modified hyper branched polyglycerol-conjugated poly (lactic-co-glycolic acid) nanoparticles: synthesis, characterization and evaluation of its brain delivery ability. J Mater Sci 2012; 23: 1891-901.
161. Prades R, Guerrero S, Araya E, Molina C, Salas E, Zurita E, et al. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomat 2012; 33: 7194-205.
162. Yemici M, Gürsoy-Özdemir Y, Caban S, Bodur E, Capan Y, Dalkara T, Transport of a caspase inhibitor across the bloodbrain barrier by chitosan nanoparticles. Methods Enzymol 2012; 508: 253-69.
163. Karatas H, Aktas Y, Gursoy-Ozdemir Y, Bodur E, Yemisci M, Caban S, et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci 2009; 29: 13761-9.
164. Pardridge WM, Kang YS, Buciak JL, Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res 1995; 12: 807-16.
165. Candela P, Gosselet F, Miller F, Buee-Scherrer V, Torpier G, Cecchelli R, et al. Physiological pathway for low-density lipoproteins across the blood-brain barrier: Transcytosis through brain capillary endothelial cells in vitro. Endothelium 2008; 15: 254-64.
166. Li Y, He H, Jia X, Lu WL, Lou J, Wei Y. A dual-targeting nano carrier based on poly (amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomat 2012; 33: 3899-908.
167. Goppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. J Drug Target 2005; 13: 179-87.
168. Koffie RM, Farrar CT, Saidi LJ, William CM, Hyman BT, Spires-Jones TL. Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 18837-42.
169. Xin HT, Xiao NL, Feng W, Wei F, Zhi CH, Peng W, et al. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomed 2011; 6: 445-52.
170. Kim HR, Andrieux K, Gil S, Taverna M, Chacun H, Desmaële D, et al. Translocation of poly (ethylene glycol-co-hexadecyl) cyanoacrylate nanoparticles into rat brain endothelial cells: Role of apolipoproteins on receptor-medicted endocytosis. Biomacromolecules 2007; 8: 793-9.
171. Re F, Cambianica I, Zona C, Sesana S, Gregori M, Rigolio R, et al. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine NBM 2011; 7: 551-9.
172. Ke W, Shao K, Huang R, Han L, Liu Y, Li J, et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethylene glycol-modified polyamidoamine dendrimer. Biomat 2009; 30: 6976-85.
173. Visser CC, Stevanovi S, Voorwinden LH, van Bloois L, Gaillard PJ, Danhof M, et al. Targeting liposomes with protein drugs to the blood-brain barrier in vitro. Eur J Pharm Sci 2005; 25: 299-305.
174. Chang J, Jallouli Y, Kroubi M, Yuan XB, Feng W, Kang CS, et al. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm 2009; 379: 285-92.
175. Lalani J, Raichandani Y, Mathur R, Lalan M, Chutani K, Mishra AK, et al. Comparative receptor based brain delivery of tramadolloaded poly (lacticco-glycolic acid) nanoparticles. J Biomed Nanotech 2012; 8: 918-27.
176. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin-and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009; 71: 251-6.
177. Dousset V, Brochet B, Deloire MS, Lagoarde L, Barroso B, Caille JM, et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. Americ J Neuroradiol 2006; 27: 1000-5.
178. Manninger SP, Muldoon LL, Nesbit G, Murillo T, Jacobs PM, Neuwelt EA. An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. Americ J Neuroradiol 2005; 26: 2290-300.
179. Kleinschnitz C, Schütz A, Nölte I, Horn T, Frank M, Solymosi L et al. In vivo detection of developing vessel occlusion in photothrombotic ischemic brain lesions in the rat by iron particle enhanced MRI. J Cereb Blood Flow Metabol 2005; 25: 1548-55.
180. Rausch M, Sauter A, Frohlich J, Neubacher U, Radu EW, Rudin M, Dynamic patterns of USPIO enhancement can be observed in macrophages after ischemic brain damage. Magn Reson Med 2001; 46:1018-22.
181. Rausch M, Baumann D, Neubacher U, Rudin M, In-vivo visualization of phagocytotic cells in rat brains after transient ischemia by USPIO. NMR Biomed 2002; 15: 278-83.
182. Schroeter M, Saleh A, Wiedermann D, Hoehn M, Jander S, Histochemical detection of ultra-small super paramagnetic iron oxide (USPIO) contrast medium uptake in experimental brain ischemia. Magn Reson Med 2004; 52: 403-6.
183. Sarin H, Kanevsky AS, Wu H, Brimacombe KR, Fung SH, Sousa AA et al. Effective trans vascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med 2008; 6: 80.
184. Schleh C, Semmler-Behnke M, Lipka J, Wenk A, Hirn S, Schäffler M et al. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicol 2012; 6: 36-46.
185. Barbu E, Molnar E, Tsibouklis J, Gorecki DC, The potential for nanoparticle-based drug delivery to the brain: overcoming the blood-brain barrier. Expert Opin Drug Deliv 2009; 6: 553-65.
186. Mahon E, Salvati A, Bombelli FB, Lynch I, Dawson KA, Designing the nanoparticle-biomolecule interface for targeting and therapeutic delivery. J Control Release 2012; 161: 164-74.
187. Sykova E, Nicholson C, Diffusion in brain extracellular space. Physiological Reviews 2008; 88: 1277-340.
188. Wolak DJ, Thorne RG, Diffusion of macromolecules in the Brain: implications for drug delivery. Molecular Pharmacology 2013; 10: 1492-504.
189. Chen H, Spagnoli F, Burris M, Rolland WB, Fajilan A, Dou H et al. Nano erythropoietin is 10-times more effective than regular erythropoietin in neuroprotection in a neonatal rat model of hypoxia-ischemia. Stroke 2012; 43: 884-7.
190. Sabel BA, Schroder U. Drug targeting system, method of its preparation and its uses. WO98056361 (1998).
191. Kreuter, J., Karkevich, D.A., Sable, B. A., Alayutdin, R. N. Drug targeting to the nervous system by nanoparticles. US6117454A (2000).
192. Sabel, B. A., Schroerder, U. Method of treating cancer. US0152636 (2003).
193. James, F.H., Daniel, N. Methods of enhancing radiation effects with metal nanoparticles. US6955639 B2 (2005).
194. Kabanov, A.V., Vinogradov, S.V. Nanogel networks including polyion polymer fragments and biological agent compositions thereof. US6696089B2 (2004).
195. Sung, H.W., Lin, Y.H., Liang, H.F., Tu, H. Nanoparticles for protein drug delivery. US7282194B2 (2007).
196. Kraig, R.P., Kaminsky, M. Compositions and method for brain specific targeted delivery of therapeutic agents. WO2007016501 (2007).
197. Miqin, Z., Olson, J.M., Raymond, S., Ellenbogen, R.G., Veiseh, O., Sun, C., Gunn, J.W. Chlorotoxin-labeled nanoparticle compositions and methods for targeting primary brain tumors. US0154965A1 (2007).
198. Akhtari, M., Engel, J. Functionalized magnetic nanoparticles and methods of use thereof. WO06102377 (2006).
199. Sharma HS, Ali SF, Dong W, Tian ZR, Patnaik R, Patnaik S, et al. Drug delivery to the spinal cord tagged with nanowire enhances neuroprotective efficacy and functional recovery following trauma to the rat spinal cord. Ann N Y Acad Sci 2007; 1122: 197-218.
200. Sharma HS. A select combination of neurotrophins enhances neuroprotection and functional recovery following spinal cord injury. Ann N Y Acad Sci 2007; 1122, 95-111.
201. Kiyatkin EA, Brown PL, Sharma HS. Brain edema and breakdown of the blood brain barrier during methamphetamine induced hyperthermia. Eur. J Neurosci 2007; 26:1242-53.
202. Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 1999; 16: 1836-42.
203. Sharma HS, Sharma A. Nanoparticles aggravate heat stress induced cognitive deficits, blood brain barrier disruption, edema formation and brain pathology. Prog Brain Res 2007; 162: 245-73.